ArticleMolecular neurobiology2025
Orexin-A Mitigates Traumatic Brain Injury by Inhibiting Neuronal Ferroptosis Through Orexin Receptor 1/Nuclear Factor Erythroid 2-Related Factor 2 Signaling Pathway.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Traumatic brain injury (TBI) contributes to neurological disability, in part through neuronal ferroptosis. Although orexin-A (OXA) attenuates TBI-induced ferroptosis and functional impairment, the underlying mechanism remains unclear. We investigated whether OXA exerts neuroprotection via the orexin receptor 1 (OX1R)/nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway through in vitro and in vivo experiments. Rat TBI models were induced by modified Feeney's method alongside Erastin-treated PC12 ferroptosis models. OX1R (intracerebroventricular) and Nrf2 (intraperitoneal) inhibitors defined pathway involvement. Neurological function was assessed through modified neurological severity scores (mNSS) and inverted screen test (IST). Pathological and molecular evaluations included Evans blue staining, hematoxylin-eosin staining, Fluoro-Jade B staining, CCK-8 assay, cell migration assays, transmission electron microscopy, biochemical assays, Western blot, quantitative polymerase chain reaction, and immunofluorescence. In the TBI rat model, OXA administration significantly reduced mNSS scores, prolonged grip latency in the IST, and attenuated blood-brain barrier disruption and neuronal damage. OXA suppressed oxidative stress, upregulated OX1R and HO-1 protein expression, elevated ferroptosis-related markers (SLC7A11 and GPX4), and promoted the nuclear translocation of Nrf2. In vitro, OXA counteracted Erastin-induced cytotoxicity in PC12 cells, ameliorated mitochondrial damage, and restored SLC7A11 and GPX4 levels. Notably, OXA's neuroprotective effects were substantially diminished upon OX1R or Nrf2 blockade. In conclusion, OXA mitigates neurological deficits, preserves blood-brain barrier integrity, reduces oxidative stress, and inhibits neuronal ferroptosis following TBI, mechanistically linked to activation of the OX1R/Nrf2 signaling pathway. These findings provide a novel therapeutic rationale for targeting ferroptosis in TBI management.
Indexed as
Identifiers
41239140What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.